ADSCC’s stem cell therapy shows promise in treating type 1 diabetes

UAE—The Abu Dhabi Stem Cells Center (ADSCC) has achieved a groundbreaking milestone in diabetes treatment, offering new hope to patients worldwide.

The center successfully conducted a pioneering therapy using umbilical cord-derived mesenchymal stem cells (UC-MSCs) for a 20-year-old Emirati patient with type 1 diabetes.

 This innovative treatment has shown significant improvements in blood sugar levels and diabetes-related antibodies just one month after administration, with ongoing progress anticipated.

As the UAE’s leading center for advanced cellular therapy, ADSCC utilized its state-of-the-art laboratories to produce the UC-MSCs used in the procedure.

This cutting-edge therapy leverages the regenerative and immune-modulatory properties of UC-MSCs, marking a significant step forward in managing diabetes.

The cells, derived from cord tissue, are known to modulate immune responses, promote tissue repair, and release bioactive factors that can potentially restore pancreatic function and reduce diabetes complications.

The therapy was carefully administered through a two-hour intravenous infusion under strict medical protocols.

 ADSCC’s multidisciplinary team closely monitored the patient before, during, and after the procedure, ensuring safety and effectiveness.

Remarkably, no adverse effects were observed, further emphasizing the therapy’s strong safety profile.

Dr. Maysoon Al Karam, Chief Medical Officer at ADSCC, highlighted this achievement as a testament to the center’s dedication to developing innovative treatments for chronic conditions like diabetes.

She emphasized the potential of UC-MSCs in reducing insulin dependency and improving overall diabetes management.

With its cutting-edge laboratories and expertise, ADSCC is well-positioned to explore broader applications of stem cell therapy for various medical conditions.

Dr. Antonio Bencomo, General Manager at ADSCC Research Center, explained that their facilities are equipped with advanced technology to isolate, expand, and preserve stem cells, ensuring high-quality and clinically viable products.

 He also noted that this successful treatment aligns with Abu Dhabi’s vision of becoming a global leader in medical innovation.

The promising results of this therapy have opened new possibilities for managing type 1 diabetes and hold potential for treating type 2 diabetes in the near future.

 ADSCC remains committed to advancing regenerative medicine, providing hope to patients with chronic illnesses, and solidifying Abu Dhabi’s role as a hub for cutting-edge healthcare solutions.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.